Quarterly report · Q2
4544.TEDINET S100S6Z0
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥116.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥260.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥134.1bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | −¥1.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥17.7bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | −¥1.6bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥22.0bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.8bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥1.6bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥20.7bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥1.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥15.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥15.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥1.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥15.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥284.6bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥297.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥287.2bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥134.4bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥147.9bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥150.1bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥150.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥157.2bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥37.1bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥44.2bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥37.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥44.2bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥37.3bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥5.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥32.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥15.8bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥7.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥29.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥18.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥6.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥7.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-32 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-12.33 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥275.52 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥273.87 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥175.63 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥275.5 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥273.84 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 52.7% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.3% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.7% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥3.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥3.1bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥2.8bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥72.4bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥72.3bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥74m |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥6.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥33.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥30.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥14.0bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥14.0bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3m |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥564m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥119.6bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥116.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3.1bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.2bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥5.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥5.1bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥1.5bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥85.1bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥85.0bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥83m |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.9bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥40.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥35.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.0bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥15.7bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥10m |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥604m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥139.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥134.1bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.1bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥19.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 524
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)ＰｗＣあらた有限責任監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)鵜 飼 千 恵 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)谷 口 寿 洋 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 134081000000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 116543000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 260908000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 17811000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | -1571000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 22010000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 15580000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | -1822000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 15676000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 20484000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 3889000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 16970000000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 157159000000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 150130000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 150047000000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 287234000000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 284578000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 297924000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 273.87 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | -32.00 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 275.52 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | 273.84 | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | 275.50 | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.547 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.527 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.503 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1YTDDuration | 15772000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYTDDuration | 5522000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 32535000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YTDDuration | -18668000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYTDDuration | -7272000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -29583000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YTDDuration | -7432000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYTDDuration | -6055000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | -5757000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1QuarterInstant | 37275000000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentQuarterInstant | 37096000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 44185000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1QuarterDuration | 175.63 | |
| Basic earnings loss per share (5-year summary) | CurrentQuarterDuration | -12.33 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 57473822 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 57473822 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 57473822 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 57473822 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |